Choosing initial MS therapy; personal, disease, and medication factors
Initiating disease modifying therapy in a patient with newly diagnosed relapsing multiple sclerosis currently offers the best opportunity to influence their subsequent disease course. This article reviews personal factors, disease presentation characteristics, and data on current disease modifying t...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Neurotherapeutics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1878747925000601 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849765704226570240 |
|---|---|
| author | Bruce A. Cohen |
| author_facet | Bruce A. Cohen |
| author_sort | Bruce A. Cohen |
| collection | DOAJ |
| description | Initiating disease modifying therapy in a patient with newly diagnosed relapsing multiple sclerosis currently offers the best opportunity to influence their subsequent disease course. This article reviews personal factors, disease presentation characteristics, and data on current disease modifying therapies from the perspective of choosing initial treatment in this setting. Although metrics for prognostication at the individual level remain unreliable, particularly for those with mild presentations, currently available data on the relative efficacy of disease modifying therapies supports offering high efficacy therapy first line to most patients with newly diagnosed relapsing multiple sclerosis. |
| format | Article |
| id | doaj-art-6ba6397ba65e440bab4bd84dc3fe1f53 |
| institution | DOAJ |
| issn | 1878-7479 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurotherapeutics |
| spelling | doaj-art-6ba6397ba65e440bab4bd84dc3fe1f532025-08-20T03:04:46ZengElsevierNeurotherapeutics1878-74792025-07-01224e0058210.1016/j.neurot.2025.e00582Choosing initial MS therapy; personal, disease, and medication factorsBruce A. Cohen0Davee Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USAInitiating disease modifying therapy in a patient with newly diagnosed relapsing multiple sclerosis currently offers the best opportunity to influence their subsequent disease course. This article reviews personal factors, disease presentation characteristics, and data on current disease modifying therapies from the perspective of choosing initial treatment in this setting. Although metrics for prognostication at the individual level remain unreliable, particularly for those with mild presentations, currently available data on the relative efficacy of disease modifying therapies supports offering high efficacy therapy first line to most patients with newly diagnosed relapsing multiple sclerosis.http://www.sciencedirect.com/science/article/pii/S1878747925000601Multiple sclerosisDisease modifying therapyInitial therapy |
| spellingShingle | Bruce A. Cohen Choosing initial MS therapy; personal, disease, and medication factors Neurotherapeutics Multiple sclerosis Disease modifying therapy Initial therapy |
| title | Choosing initial MS therapy; personal, disease, and medication factors |
| title_full | Choosing initial MS therapy; personal, disease, and medication factors |
| title_fullStr | Choosing initial MS therapy; personal, disease, and medication factors |
| title_full_unstemmed | Choosing initial MS therapy; personal, disease, and medication factors |
| title_short | Choosing initial MS therapy; personal, disease, and medication factors |
| title_sort | choosing initial ms therapy personal disease and medication factors |
| topic | Multiple sclerosis Disease modifying therapy Initial therapy |
| url | http://www.sciencedirect.com/science/article/pii/S1878747925000601 |
| work_keys_str_mv | AT bruceacohen choosinginitialmstherapypersonaldiseaseandmedicationfactors |